Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

News > All

Total search results: 16877 | Ordered by Source (ascending)
1 2 3 ... 167 168 169  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
10x Genomics Inc.. (1/7/19). "Press Release: 10x Genomics Lands New Financing". Pleasanton, CA. 2019-01-07
10x Genomics Inc.. (12/10/18). "Press Release: 10x Genomics Acquires Spatial Transcriptomics". Pleasanton, CA. 2018-12-10
10x Genomics Inc.. (4/26/18). "Press Release: 10x Genomics Completes $50 Million Series D Financing and $75M Debt Facility". Pleasanton, CA. 2018-04-26
14M Genomics Ltd.. (12/16/14). "Press Release: 14M Genomics and Syncona Sign £12.5 Million Financing to Develop Cancer Genomic Diagnostics in Partnership with the Wellcome Trust Sanger Institute". 2014-12-16
14M Genomics Ltd.. (2/10/15). "Press Release: 14M Genomics and the Haematological Malignancy Research Network Collaborate on Clinical Genomic Profiling in Blood and Lymphatic Cancers". Cambridge. 2015-02-10
14M Genomics Ltd.. (3/10/15). "Press Release: 14M Genomics and the European Organisation for Research and Treatment of Cancer Collaborate on Genomic Profiling for Clinical Trials". Cambridge. 2015-03-10
14M Genomics Ltd.. (7/14/15). "Press Release: 14M Genomics Appoints Alan Schafer as Chief Executive Officer". Cambridge. 2015-07-14
1st Detect Corporation. (3/6/12). "Press Release: 1st Detect Awarded EU Patent for Chemical Detection Technology". Austin, TX. 2012-03-06
1st Detect Corporation. (9/25/12). "Press Release: 1st Detect MMS-1000 Launched in European Union with TransGlobal Distributors". Austin, TX. 2012-09-25
2B BlackBio S.L.. (10/25/11). "Press Release: BlackBio Gets more than 2 Million Euros after Capital Increase and Public Funding". 2011-10-25
2B BlackBio S.L.. (2/15/10). "Press Release: BlackBio, Making Personalized Medicine a Reality. Established in 2009 BlackBio Is a Biotechnology Spin-off Company Committed to Making Personalized Medicine an Affordable Reality". 2010-02-15
2B BlackBio S.L.. (2/27/12). "Press Release: The Spanish Biotechnological Companies, Biotools and 2B BlackBio, Reach an Agreement with the Mexican Pharmaceutics Silanes Laboratories". 2012-02-27
2cureX ApS. (10/21/09). "Press Release: 2cureX Announces Issuance of Patent On Its ChemoCellomics Technology". Copenhagen. 2009-10-21
2cureX ApS. (12/6/10). "Press Release: The Danish Council for Strategic Research Supports 2cureX and Its Academic Partners". Copenhagen. 2010-12-06
2cureX ApS. (6/8/10). "Press Release: 2cureX Announces Issuance of Final Patent Completing the Protection of the ChemoCellomics Technology". Copenhagen. 2010-06-08
3B Pharmaceuticals GmbH. (11/20/18). "Press Release: Ipsen and 3BP Announce First Patient Dosed in Phase I/II Study for First-in-class Radionuclide (IPN01087)". Paris. 2018-11-20
3P Biopharmaceuticals S.L.. (12/20/13). "Press Release: Dámaso Molero, a New Member of the Board of Directors of Asebio". 2013-12-20
3P Biopharmaceuticals S.L.. (4/14/14). "Press Release: 3P Biopharmaceuticals Invests 630,000€ in Increasing Its Capacity Development". 2014-04-14
3P Biopharmaceuticals S.L.. (4/23/15). "Press Release: 3P Biopharmaceuticals Produces a Cellular Drug for the First Clinical Trial of Acute Myocardial Infarction with Allogeneic Cardiac Stem Cells". 2015-04-23
3P Biopharmaceuticals S.L.. (5/5/15). "Press Release: 3P Biopharmaceuticals Acquires a Mass Spectrometer". 2015-05-05
3P Biopharmaceuticals S.L.. (7/10/13). "Press Release: 3P Biopharmaceuticals Will Participate in a Major European Project Aiming to Develop a Universal Influenza Virus Vaccine". 2013-07-10
4-Antibody AG. (1/29/13). "Press Release: 4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets". Basel & New York, NY. 2013-01-29
4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel. 2012-10-08
4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel. 2010-03-16
4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel. 2011-08-16
4-Antibody AG. (9/11/09). "Press Release: Retrocyte Display Technology Patent Applications Published". Basel. 2009-09-11
4-Antibody AG. (9/19/11). "Press Release: 4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration". Basel. 2011-09-19
4-Antibody AG. (9/21/09). "Press Release: 4-Antibody Received Notice of Allowance for U.S. Patent Application Describing the Hu-PAC Technology". Basel. 2009-09-21
4D Molecular Therapeutics. (4/30/18). "Press Release: 4DMT and Roche Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products". Emeryville, CA. 2018-04-30
4D Pharma plc. (12/8/15). "Press Release: Placing to Raise £30 Million by the Issue of 3,797,469 New Ordinary Shares at 790p per Share". 2015-12-08
4D Pharma plc. (2/10/16). "Press Release: Acquisition [of Tucana Health Ltd.]". 2016-02-10
4DCell Fate Project. (2/13/12). "Press Release: Cell Fate in 4D. Bringing together European Excellence to Uncover the Mechanisms at Work that Determine Cell Fate". Barcelona. 2012-02-13
4P-Pharma. (9/1/16). "Press Release: Signature of a License Agreement with 4P-Pharma for the Development of an Anti-cancer Drug". Talence. 2016-09-01
4SC AG. (1/12/15). "Press Release: Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join the Supervisory Board of 4SC AG". Planegg-Martinsried. 2015-01-12
4SC AG. (1/13/15). "Press Release: Beyond Research Initiative of 4SC Discovery and Crelux Reaches First Milestone in Drug Discovery Project for Helmholtz Zentrum München". Planegg-Martinsried & Munich. 2015-01-13
4SC AG. (1/19/12). "Press Release: 4SC’s Cancer Compound Resminostat Meets Primary Endpoint in Phase II Trial in Advanced Liver Cancer (HCC) ahead of Schedule". Planegg-Martinsried. 2012-01-19
4SC AG. (1/20/11). "Press Release: 4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-mutant Colorectal Cancer Patients with Resminostat". Planegg-Martinsried. 2011-01-20
4SC AG. (1/21/11). "Press Release: 4SC Presents Update on Phase II SHELTER Trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium". Planegg-Martinsried. 2011-01-21
4SC AG. (1/23/15). "Press Release: 4SC AG Plans Extraordinary General Meeting and Reduction of Share Capital". Planegg-Martinsried. 2015-01-23
4SC AG. (1/7/11). "Press Release: 4SC Announces First-in-Man Phase I Results for 4SC-203". Planegg-Martinsried. 2011-01-07
4SC AG. (1/8/13). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in Europe". Planegg-Martinsried. 2013-01-08
4SC AG. (10/1/12). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in China". Planegg-Martinsried. 2012-10-01
4SC AG. (10/10/17). "Press Release: Resminostat Demonstrates Potential to Significantly Alleviate Itching in CTCL Patients". Planegg-Martinsried. 2017-10-10
4SC AG. (10/21/16). "Press Release: Dr Daniel Vitt to Step Down as CDO/CSO and from the Management Board at the End of 2016". Planegg-Martinsried. 2016-10-21
4SC AG. (10/23/12). "Press Release: 4SC Discovery Receives Research Grant of EUR 600,000 for Development of Personalised Cancer Drugs". Planegg-Martinsried. 2012-10-23
4SC AG. (10/26/10). "Press Release: 4SC Announces Initial Phase II Data from the SAPHIRE Study with Resminostat at the 8th International Symposium on Hodgkin Lymphoma". Planegg-Martinsried. 2010-10-26
4SC AG. (10/26/17). "Press Release: 4SC Provides Q3 and 9M 2017 Update". Planegg-Martinsried. 2017-10-26
4SC AG. (11/11/10). "Press Release: 4SC Reports First Nine Months Financial Results 2010". Planegg-Martinsried. 2010-11-11
4SC AG. (11/16/10). "Press Release: 4SC to Highlight the Potential of Its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium »on Molecular Targets and Cancer Therapeutics«". Planegg-Martinsried. 2010-11-16
4SC AG. (11/4/10). "Press Release: 4SC’s Vidofludimus Meets Primary Endpoint with Excellent Response Rate in IBD Trial. Vidofludimus Generates a Response Rate of 88.5% for the Treatment of Patients with Crohn’s Disease and Ulcerative Colitis". Planegg-Ma 2010-11-04
4SC AG. (11/4/13). "Press Release: AiCuris, 4SC Discovery and Crelux Announce Drug Discovery Collaboration". Planegg-Martinsried & Wuppertal. 2013-11-04
4SC AG. (11/6/14). "Press Release: 4SC Announces Financial Results for the First Nine Months and the Third Quarter of 2014". Planegg-Martinsried. 2014-11-06
4SC AG. (11/7/11). "Press Release: 4SC Presents Encouraging Final Results of Vidofludimus Phase IIb COMPONENT Study in Rheumatoid Arthritis at ACR Meeting in Chicago". Planegg-Martinsried. 2011-11-07
4SC AG. (11/7/13). "Press Release: 4SC Announces Improved Financial Results for the Third Quarter and First Nine Months of 2013". Planegg-Martinsried. 2013-11-07
4SC AG. (11/8/11). "Press Release: 4SC Announces Financial Results for the Third Quarter and First Nine Months of 2011". Planegg-Martinsried. 2011-11-08
4SC AG. (11/8/12). "Press Release: 4SC’s Successful Development Continues in Third Quarter of 2012. Consolidated Financial Results Improved in Third Quarter and First Nine Months". Planegg-Martinsried. 2012-11-08
4SC AG. (12/12/12). "Press Release: 4SC Announces Positive Interim Results from Clinical Phase I/II Trial with Anti-cancer Compound Resminostat in Colorectal Cancer". Planegg-Martinsried. 2012-12-12
4SC AG. (12/14/11). "Press Release: 4SC Forms Subsidiary to Commercialise Innovative Early-stage Drug Research Programmes and Strengthen Revenue from Research Collaborations". Planegg-Martinsried. 2011-12-14
4SC AG. (12/17/12). "Press Release: 4SC Discovery and BioNTech Announce Exclusive Research and License Agreement for 4SC’s TLR Agonists for Cancer Immunotherapy". Planegg-Martinsried & Mainz. 2012-12-17
4SC AG. (12/20/10). "Press Release: 4SC Completes Enrolment of the Phase IIb COMPONENT Trial with Vidofludimus in Rheumatoid Arthritis". Planegg-Martinsried. 2010-12-20
4SC AG. (12/22/10). "Press Release: 4SC Receives EU Grant to Identify New Drugs for the Treatment of Rheumatoid Arthritis as Part of a Consortium". Planegg-Martinsried. 2010-12-22
4SC AG. (12/7/11). "Press Release: 4SC Obtains Key Patent for Lead Anti-cancer Compound Resminostat in Japan". Planegg-Martinsried. 2011-12-07
4SC AG. (12/9/14). "Press Release: 4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205 in Cancer Patients Using Novel Continuous Dosing Scheme". Planegg-Martinsried. 2014-12-09
4SC AG. (2/1/18). "Press Release: Positive DSMB Safety Review of 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried. 2018-02-01
4SC AG. (2/10/15). "Press Release: 4SC's Associated Company Panoptes Pharma Concludes License Agreement with Mediolanum for Compound PP-001 for Inflammatory Eye Diseases". Planegg-Martinsried. 2015-02-10
4SC AG. (2/12/14). "Press Release: Continued Funding of 4SC AG. Investor Undertakes to Subscribe to Convertible Notes for up to EUR 15 Million Nominally [Ad hoc Announcement] ". Planegg-Martinsried. 2014-02-12
4SC AG. (2/20/13). "Press Release: 4SC Discovery and BioNTech Launch Strategic Cancer Therapy Research Partnership". Planegg-Martinsried & Mainz. 2013-02-20
4SC AG. (2/23/11). "Press Release: 4SC Announces Capital Increase". Planegg-Martinsried. 2011-02-23
4SC AG. (2/26/13). "Press Release: 4SC Discovery and Leo Pharma Announce Exclusive Research and License Agreement for Inflammatory Skin Diseases". Planegg-Martinsried & Ballerup. 2013-02-26
4SC AG. (2/6/17). "Press Release: 4SC AG to Present at the 19th Annual BIO CEO & Investor Conference 2017". Planegg-Martinsried. 2017-02-06
4SC AG. (2/6/19). "Press Release: First Patient Enrolled in Phase II Study EMERGE of Domatinostat (4SC-202) in Gastrointestinal Cancer". Planegg-Martinsried. 2019-02-06
4SC AG. (3/1/12). "Press Release: 4SC Receives Patent Protection for Its Oncology Compound Resminostat in Taiwan and Three other Asian Growth Markets". Planegg-Martinsried. 2012-03-01
4SC AG. (3/12/13). "Press Release: Ad hoc. Notice of Loss Pursuant to Section 92 (1) German Stock Corporation Act (Aktiengesetz, AktG)". Planegg-Martinsried. 2013-03-12
4SC AG. (3/20/14). "Press Release: 4SC Discovery Collaborates with Heidelberg University Hospital and Receives EUR 1.3 Million for Research and Preclinical Development of New Malaria Drug". Planegg-Martinsried. 2014-03-20
4SC AG. (3/21/18). "Press Release: 4SC AG Announces Results for Financial Year 2017". Planegg-Martinsried. 2018-03-21
4SC AG. (3/24/16). "Press Release: Chairman of the Management Board Enno Spillner Will Not Extend His Current Term of Office, But Will Leave the Company After a Transitional Period Ending 30 June 2016". Planegg-Martinsried. 2016-03-24
4SC AG. (3/25/13). "Press Release: 4SC Announces Financial Results for a Successful Year 2012". Planegg-Martinsried. 2013-03-25
4SC AG. (3/25/15). "Press Release: 4SC Publishes Results for Financial Year 2014". Planegg-Martinsried. 2015-03-25
4SC AG. (3/26/14). "Press Release: 4SC Publishes Results for Financial Year 2013 and Announces Changes to the Management Board". Planegg-Martinsried. 2014-03-26
4SC AG. (3/27/18). "Press Release: Yakult Honsha Joins 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL – 4SC Receives Milestone Payment". Planegg-Martinsried. 2018-03-27
4SC AG. (3/29/12). "Press Release: 4SC Announces Financial Results 2011". Planegg-Martinsried. 2012-03-29
4SC AG. (3/30/16). "Press Release: 4SC Announces Results for Financial Year 2015". Planegg-Martinsried. 2016-03-30
4SC AG. (3/4/14). "Press Release: 4SC AG Issues First Tranche of Convertible Notes with a Nominal amount of EUR 500,000 to Yorkville". Planegg-Martinsried. 2014-03-04
4SC AG. (3/6/13). "Press Release: 4SC AG. Dr Ulrich Dauer to Step Down as CEO and Member of the Management Board on 31 March 2013, His Successor Will Be CFO Enno Spillner". Planegg-Martinsried. 2013-03-06
4SC AG. (4/1/15). "Press Release: Dr Susanne Danhauser-Riedl Joins 4SC as Chief Medical Officer to Strengthen Management and Clinical Development Team". Planegg-Martinsried. 2015-04-01
4SC AG. (4/11/18). "Press Release: Yakult Honsha Recruits First Japanese Patient in 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried. 2018-04-11
4SC AG. (4/14/11). "Press Release: 4SC and Yakult Hinsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat". Planegg-Martinsried & Tokyo. 2011-04-14
4SC AG. (4/14/15). "Press Release: 4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan". Planegg-Martinsried & Singapore. 2015-04-14
4SC AG. (4/15/14). "Press Release: 4SC Discovery Receives EU Grant Worth EUR 450,000 for the Research of New Epigenetic Compounds against Stroke". Planegg-Martinsried. 2014-04-15
4SC AG. (4/17/18). "Press Release: 4SC at AACR – Broadened Clinical Options for 4SC-202". Planegg-Martinsried. 2018-04-17
4SC AG. (4/18/12). "Press Release: 4SC Discovery and Crelux Enter into a Strategic Alliance for Joint Drug Discovery Services". Planegg-Martinsried. 2012-04-18
4SC AG. (4/19/18). "Press Release: Phase II Study of 4SC’s Resminostat in Biliary Tract Cancer in Japan Is Initiated". Planegg-Martinsried. 2018-04-19
4SC AG. (4/2/12). "Press Release: Henkel and 4SC Discovery Start Research Collaboration in Compound Screening". Planegg-Martinsried. 2012-04-02
4SC AG. (4/29/16). "Press Release: 4SC Sells Operations of Its Discovery Division [Ad hoc announcement according to $ 15 WpHG]". Planegg-Martinsried. 2016-04-29
4SC AG. (4/30/12). "Press Release: 4SC Receives Milestone Payment from Research Collaboration with SKK". Planegg-Martinsried. 2012-04-30
4SC AG. (5/10/11). "Press Release: 4SC Announces Financial Results for the First Quarter 2011". Planegg-Martinsried. 2011-05-10
4SC AG. (5/14/13). "Press Release: 4SC Significantly Improves Operating Result in First Quarter of 2013 and Resolves to Focus Its Development Strategy". Planegg-Martinsried. 2013-05-14
4SC AG. (5/27/16). "Press Release: 4SC Provides Headline Results from Yakult Honsha’s Phase II Trial of Resminostat in Combination with Sorafenib as First Line Therapy in Liver Cancer (Ad hoc announcement according to § 15 WpHG)". Planegg-Martinsried. 2016-05-27
4SC AG. (5/30/13). "Press Release: 4SC Gives Update on the Clinical Development of Its Lead Cancer Compound Resminostat". Planegg-Martinsried. 2013-05-30
4SC AG. (5/31/16). "Press Release: 4SC Enters into Licensing and Development Partnership with Link Health for the Cancer Compound 4SC-205 in China". Planegg-Martinsried. 2016-05-31
1 2 3 ... 167 168 169  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px

» top